NASDAQ:ATRA
Atara Biotherapeutics Stock News
$0.546
-0.0197 (-3.48%)
At Close: May 09, 2024
Kiadis Pharma (KIADF) Receives a Buy from Canaccord Genuity
10:08am, Friday, 01'st May 2020
Canaccord Genuity analyst John Newman maintained a Buy rating on Kiadis Pharma (KIADF) yesterday and set a price target of EUR4.00. The company's shares
Kiadis Pharma (KIADF) Receives a Buy from Canaccord Genuity
10:08am, Friday, 01'st May 2020
Canaccord Genuity analyst
John Newman
maintained a
Buy
rating on Kiadis Pharma (
KIADF
–
Research Report
) yesterday and set a price target of
EUR4.00
. The company’s shares closed last Monday at
Agios Pharma (AGIO) Gets a Buy Rating from Canaccord Genuity
10:08am, Friday, 01'st May 2020
In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Agios Pharma (AGIO), with a price target of $72.00. The
Agios Pharma (AGIO) Gets a Buy Rating from Canaccord Genuity
10:08am, Friday, 01'st May 2020
In a report released yesterday,
John Newman
from Canaccord Genuity maintained a
Buy
rating on Agios Pharma (
AGIO
–
Research Report
), with a price target of
$72.00
. The company’s shares closed l
Mizuho Securities Reaffirms Their Hold Rating on Amgen (AMGN)
09:44pm, Thursday, 30'th Apr 2020
In a report released today, Salim Syed from Mizuho Securities reiterated a Hold rating on Amgen (AMGN), with a price target of $215.00. The company's
Mizuho Securities Reaffirms Their Hold Rating on Amgen (AMGN)
09:43pm, Thursday, 30'th Apr 2020
In a report released today, Salim Syed from Mizuho Securities reiterated a Hold rating on Amgen (AMGN – Research Report),
Atara Biotherapeutics to Announce First Quarter 2020 Financial Results on Wednesday, May 6, 2020
08:01pm, Thursday, 30'th Apr 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today
Atara Biotherapeutics Appoints Biotech and Finance Industry Veteran Ron Renaud as Non-Executive Chair of the Board of Directors
12:30pm, Thursday, 30'th Apr 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today
Atreca (BCEL) Receives a Buy from Canaccord Genuity
10:32am, Thursday, 30'th Apr 2020
Canaccord Genuity analyst John Newman maintained a Buy rating on Atreca (BCEL) yesterday and set a price target of $23.00. The company's shares closed
Atreca (BCEL) Receives a Buy from Canaccord Genuity
10:31am, Thursday, 30'th Apr 2020
Canaccord Genuity analyst John Newman maintained a Buy rating on Atreca (BCEL – Research Report) yesterday and set a price
Allogene Therapeutics (ALLO) Gets a Buy Rating from Canaccord Genuity
10:31am, Thursday, 30'th Apr 2020
In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Allogene Therapeutics (ALLO), with a price target of $36.00.
Allogene Therapeutics (ALLO) Gets a Buy Rating from Canaccord Genuity
10:31am, Thursday, 30'th Apr 2020
In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Allogene Therapeutics (ALLO – Research
Mizuho Securities Sticks to Their Buy Rating for Gilead Sciences (GILD)
02:02pm, Wednesday, 29'th Apr 2020
In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Gilead Sciences (GILD), with a price target of $81.00. The
Mizuho Securities Sticks to Their Buy Rating for Gilead Sciences (GILD)
02:02pm, Wednesday, 29'th Apr 2020
In a report released today,
Salim Syed
from Mizuho Securities maintained a
Buy
rating on Gilead Sciences (
GILD
–
Research Report
), with a price target of
$81.00
. The company’s shares closed las
Canaccord Genuity Remains a Buy on Aptose Biosciences (APTO)
10:08am, Tuesday, 28'th Apr 2020
Canaccord Genuity analyst John Newman maintained a Buy rating on Aptose Biosciences (APTO) yesterday and set a price target of $13.00. The company's
